PET46
Live / Applied — Statement of use — registration review complete (as of 28 Oct 2026)
What this means for you
Not registered yet, but its 18 Jul 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98655491
- Mark type
- Word mark
- Filed
- 18 Jul 2024
- Published for opposition
- 08 Apr 2025
- Attorney of record
- Harold Milstein
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical products for the detection of cancer; diagnostic antibody biomarker reagents for medical purposes, namely, for the diagnosis of cancer.
Owner
- KYNTRA BIO, INC., SAN FRANCISCO, CA, US
- FibroGen, Inc., San Francisco, CA, US
- FibroGen, Inc., San Francisco, CA, US
Prosecution history
- 28 Oct 2026 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 28 Oct 2026 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 23 Sept 2026 — STATEMENT OF USE PROCESSING COMPLETE
- 01 Sept 2026 — USE AMENDMENT FILED
- 01 Sept 2026 — TEAS STATEMENT OF USE RECEIVED
- 22 May 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 21 May 2026 — SOU EXTENSION 2 GRANTED
- 21 May 2026 — SOU EXTENSION 2 FILED
- 21 May 2026 — SOU TEAS EXTENSION RECEIVED
- 06 May 2026 — AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
- 11 Nov 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 10 Nov 2025 — SOU EXTENSION 1 GRANTED
- 10 Nov 2025 — SOU EXTENSION 1 FILED
- 10 Nov 2025 — SOU TEAS EXTENSION RECEIVED
- 03 Jun 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT